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Background-—The histological diagnosis of cardiac sarcoidosis (CS) is based on the presence of myocardial granulomas; however,
the sensitivity of endomyocardial biopsy is relatively low. We investigated whether immunocompetent cells including dendritic cells
(DC) and macrophages in nongranuloma sections of endomyocardial biopsy samples could be histopathological surrogates for CS
diagnosis.
Methods and Results-—The numbers of DC and macrophages were investigated in 95 consecutive CS patients and 50 patients
with nonischemic cardiomyopathy as controls. All patients underwent endomyocardial biopsy, and immunohistochemical staining
was performed on all samples. We examined these immunocompetent cells in nongranuloma sections in CS patients diagnosed by
the presence of myocardial granulomas (n=26) and in CS patients without myocardial granulomas diagnosed by the Japanese
Ministry of Health Welfare 2007 criteria (n=65) or the Heart Rhythm Society 2014 criteria (n=26). In CS patients with and without
myocardial granulomas, CD209+ DC and CD68+ macrophages were more frequently observed (P<0.01) and CD163+M2
macrophages were less frequently observed (P<0.01) in nongranuloma sections compared to controls. Furthermore, the
combination of decreased CD163+M2/CD68+ macrophage ratio and increased number of CD209+ DC in nongranuloma sections of
CS patients demonstrated high speciﬁcity (100%, 95% CI 92.7–100) for CS diagnosis with each diagnostic criteria and the presence
of myocardial granulomas.
Conclusions-—Increased number of DC and decreased M2 among all macrophages in nongranuloma sections of myocardium
showed high speciﬁcity for CS diagnosis, suggesting DC and macrophage phenotypes as histopathological surrogates for the
diagnosis of CS. ( J Am Heart Assoc. 2016;5:e004019 doi: 10.1161/JAHA.116.004019)
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C ardiac involvement has been recognized as a determi-nant of worse clinical outcomes in sarcoidosis
patients;1,2 therefore it should be detected earlier and treated
with steroids for a long-term period.3,4 However, clinicians
often have difﬁculty in diagnosing cardiac sarcoidosis (CS)
accurately because of few currently accepted international
guidelines, especially in extracardiac sarcoidosis patients with
latent myocardial damage.5 To date, there are 3 proposed
major diagnostic guidelines: the Japanese Ministry of Health
and Welfare’s criteria modiﬁed in 2007 (JMHW 2007),6 the
World Association for Sarcoidosis and Other Granulomatous
Disorders’ criteria modiﬁed in 2014 (WASOG 2014),7 and the
Heart Rhythm Society expert consensus in 2014 (HRS 2014).8
Of them, the WASOG 2014 and HRS 2014 criteria mandate
the presence of granulomas in either myocardium or other
extracardiac tissue for the diagnosis of CS. Nevertheless,
endomyocardial biopsy (EMB) and extracardiac biopsy have
low sensitivity because of the focal nature of the disease, and
indeed granulomas in myocardium can be identiﬁed in less
than 30% of CS patients.9 On the other hand, the JMHW 2007
criteria do not mandate positive biopsy for CS diagnosis, but
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they may in time afford overdiagnosis. To overcome these
limitations, novel histopathological surrogates for the diagno-
sis of CS are strongly warranted.
Dendritic cells (DC) are professional antigen-presenting
cells, which are found in all organ systems, including the
myocardium, and play crucial roles not only in the postinfarc-
tion healing process after myocardial infarction,10,11 but also
in the pathogenesis of sarcoidosis, based on immunohisto-
chemical analyses of lung and muscle.12,13 Macrophages are
another key player in the granuloma formation following the
stimuli of DC and T-cells. Recently, macrophages have been
able to be divided into 2 phenotypes, M1 (pro-inﬂammatory)
and M2 (anti-inﬂammatory), which differ phenotypically and,
almost certainly, functionally.14
Therefore, we hypothesized that DC and macrophages
might also be associated with the development of granulomas
in the myocardium and provide a histopathological clue for
the diagnosis of CS. The purpose of this study was ﬁrst to
investigate whether DC and macrophages are observed in
sarcoid granulomas and their surrounding areas in myocar-
dium, and second to examine the clinical application of DC
and macrophage phenotypes in relation to CS diagnosis by
evaluating these immunocompetent cells in nongranuloma
sections of EMB samples from CS patients with and without
myocardial granulomas.
Methods
Study Population and Clinical Data Collection
We examined 186 consecutive patients with newly diagnosed
CS based on the clinical manifestations and/or histological
ﬁndings, without coronary artery disease, who were admitted
to the National Cerebral and Cardiovascular Center between
September 1979 and December 2015, and the Hokkaido
University Hospital between April 2001 and June 2015.
Patients who did not undergo EMB at the time of CS diagnosis
and before immunosuppressive treatment (n=72), did not
have appropriate EMB samples for immunohistochemical
analyses (n=11), or did not meet the diagnostic criteria
deﬁned in the JMHW 2007 (n=8) were excluded. Brieﬂy,
according to the JMHW 2007 criteria, a deﬁnite diagnosis of
CS was made on the basis of the presence of granulomas in
the myocardium, or clinical and/or histological ﬁndings
meeting clinical criteria for CS with extracardiac involvement
of at least 1 organ. Finally, 95 CS patients were included in
this study (Figure 1). We also examined 50 consecutive
patients with nonischemic and noninﬂammatory cardiomy-
opathy who underwent EMB at Hokkaido University Hospital
between October 2012 and January 2015, and at National
Cerebral and Cardiovascular Center Hospital between Febru-
ary 2015 and April 2015, based on a widely accepted
scientiﬁc statement (Figure 1).15 The study protocol was
approved by our institutional review committee (M27-021)
and conformed to the principles of the Declaration of Helsinki,
and the subjects gave informed consent.
We collected the following data: age, sex, echocardio-
graphic ﬁndings, baseline fatal ventricular tachycardia,
advanced atrioventricular block, extracardiac organ involve-
ment, laboratory ﬁndings, cardiovascular medication, and
ﬁndings of imaging modalities including gallium scintigraphy
and 18F-ﬂuorodeoxyglucose–positron emission tomography
(FDG-PET) at the time of diagnosis. Regarding FDG-PET
ﬁndings, speciﬁc focal uptake of FDG was deﬁned as positive
based on previous reports.16,17 The ﬁndings of gallium
scintigraphy and FDG-PET were determined by the consensus
of 2 experienced radiologists. Venous blood samples were
serially obtained to measure plasma angiotensin-converting
enzyme activity, lysozyme, and brain natriuretic peptide levels.
Histological and Immunohistochemical Staining
We examined immunocompetent cells in myocardial granulo-
mas (n=30), and then examined those in nongranuloma
Figure 1. Study population. CS indicates cardiac sarcoidosis;
DCM, dilated cardiomyopathy; EMB, endomyocardial biopsy; HCM,
hypertrophic cardiomyopathy; HHD, hypertensive heart disease;
HRS, Heart Rhythm Society; JMHW, Japanese Ministry of Health and
Welfare.
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sections of myocardium in CS patients with myocardial
granulomas (n=26) and CS patients without myocardial
granulomas diagnosed by the JMHW 2007 criteria (n=65) or
the HRS 2014 criteria (n=26) (Figure 1).
We used a transcatheter method to collect EMB samples
from 3 to 5 different sites in the right ventricular septum. For
histological analyses, the EMB samples were ﬁxed in formalin
and embedded in parafﬁn using standard histological proce-
dures. The tissue was cut to yield 5-lm-thick cross sections.
The sections were subsequently stained with hematoxylin and
eosin and Masson’s trichrome stain to determine the extent of
ﬁbrosis.
Immunohistochemical examinations were performed on
5-lm-thick formalin-ﬁxed and parafﬁn-embedded tissue
sections. All steps were performed on a Leica Bond III
automated system (Leica Microsystems, Wetzlar, Germany)
according to the manufacturer’s instructions as previously
reported.11 Brieﬂy, specimens were deparafﬁnized and
antigen was retrieved on the instrument. All slides were
incubated with primary antibodies against CD3 (diluted
1:10; Dako, Glostrup, Denmark), CD68 (diluted 1:1000,
Dako), CD163 (diluted 1:10; Abcam, Cambridge, UK), and
CD209 (1:1000, BD Pharmingen, Franklin Lakes, NJ) for
16 minutes, followed by incubation with a mouse–rabbit–
horseradish peroxidase polymer and 3,30-diaminobenzidine
substrate. The sections were then incubated in primer (anti-
rabbit and anti-mouse) for 8 minutes. The primary antibody
was omitted from these protocols as a negative control.
The sections were subsequently counterstained with hema-
toxylin.
Quantitative Analyses of Myocardial
Immunocompetent Cells
Quantitative analyses were performed by 2 trained techni-
cians without knowledge of the patients’ backgrounds. In
nongranuloma sections in the 3 CS and control groups, a
representative section for analysis was randomly chosen by 1
technician in a low-magniﬁcation whole view of 3 to 5
sections obtained by EMB. Stained immunocompetent cells
were counted at a magniﬁcation of 9100 in 10 representative
parts (0.01 mm2/part) that were randomly chosen by 2
technicians in the representative section, using ImageJ
software (version 1.50b; National Institutes of Health,
Bethesda, MD). For each part, total cell numbers/10 repre-
sentative parts (0.01 mm2/part) in high-power ﬁelds were
counted and demonstrated the cell numbers per 0.1 mm2.
Statistical Analyses
Continuous data were expressed as median (interquartile
range). The 2 groups were compared using the Wilcoxon
rank sum test for continuous variables. Categorical
variables were reported as frequencies with percentages
and compared between the 2 groups using the Fisher’s
exact test. Receiver-operating characteristic (ROC) curve
analysis was used to determine optimal cut-off values for
selected variables regarding immunocompetent cell counts
in granuloma-negative sections in each group, to obtain a
deﬁnite CS diagnosis with JMHW 2007 and HRS 2014
criteria and the presence of myocardial granulomas. The
best cut-off point was calculated by obtaining the
maximum value of Youden index (sensitivity+speciﬁcity1).
The area under the ROC curve was determined as a
summary measure for diagnostic accuracy of the variables.
Sensitivity and speciﬁcity were calculated for each cut-off
value, using standard techniques. A logistic regression
analysis was also performed to check the relationship
between diagnostic accuracy of myocardial DC and
macrophage phenotypes, and sex. All statistical analyses
were performed with SPSS for Windows version 23.0
(IBM Corp, Armonk, NY) and STATA 14 (Stata Corp,
College Station, TX). Statistical signiﬁcance was deﬁned as
a P value of <0.05.
Results
Baseline Characteristics
Patients with CS had signiﬁcantly higher prevalence of
female sex, basal interventricular thinning, positive ﬁndings
of gallium scintigraphy and FDG-PET, and higher serum
angiotensin-converting enzyme level compared with the
control group, regardless of the presence of granulomas in
the myocardium and diagnostic criteria (Table 1). Other
characteristics with regard to age and left ventricular
ejection fraction did not differ statistically in the CS and
control groups (Table 1).
Immunocompetent Cells in Myocardium With
Sarcoid Granulomas
Figure 2 shows a representative section showing immuno-
competent cells in myocardium with sarcoid granuloma. A
large number of CD68-positive macrophages were found in
the central core of granulomas, and CD3-positive T-cells were
present in the central core and its surrounding area. CD209-
positive DC were found mainly in the lymphocyte layer of
granulomas (median number=19.5 [interquartile range: 14.3–
22.0]/0.1 mm2), and were rarely found in the central core. On
the other hand, CD163-positive M2 macrophages were less
frequently observed in the center and the surrounding area of
granulomas (median number=7.0 [interquartile range: 2.8–
8.3]/0.1 mm2).
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Immunocompetent Cells in Nongranuloma
Sections of CS Patients With and Without
Myocardial Granulomas
From immunohistochemical examination of nongranuloma
sections of CS patients with and without myocardial
granulomas, the numbers of CD209-positive DC and CD68-
positive macrophages were signiﬁcantly higher, and that of
CD163-positive M2 macrophages was lower in the CS
groups compared to the control group. Moreover, the
CD163/CD68 macrophage ratio was also signiﬁcantly lower
in the CS groups compared to the control group. However,
the number of CD3-positive T-cells was not statistically
different among the CS and control groups, except for
nongranuloma sections of CS patients with myocardial
granulomas (Figure 3A and 3B).
Diagnostic Accuracy of Myocardial DC and
Macrophage Phenotypes in Nongranuloma
Sections for CS Diagnosis
ROC curves for the CD163/CD68 macrophage ratio, number
of CD68-positive macrophages, and CD209-positive DC for
predicting CS with each of the JMHW 2007 and HRS 2014
criteria and the presence of myocardial granulomas are shown
in Figure 4A through 4C. The area under the ROC curve of the
ROC curve for CD163/CD68 macrophage ratio showed the
best area under the ROC curve with each criterion and
the presence of myocardial granulomas. At the cut-off value,
the combination of decreased CD163/CD68 macrophage
ratio and increased number of CD209-positive DC in
nongranuloma sections of CS patients with and without
myocardial granulomas also demonstrated the highest
Table 1. Baseline Characteristics of Study Population
Variable
Cardiac Sarcoidosis
Control
(n=50)
Myocardial Granulomas
(n=26)
No Myocardial Granulomas
Diagnosed by JMHW 2007
(n=65)
Diagnosed by HRS 2014
(n=26)
Age, y 56 (48–66) 62 (55–68) 59 (54–68) 59 (44–70)
Female sex, n (%) 20 (77)* 46 (71)* 18 (69)* 17 (34)
LVEF, % 34 (27–42) 38 (31–49) 40 (33–53) 33 (22–55)
Basal IVS thinning, n (%) 15 (58)* 31 (48)* 14 (54)* 0 (0)
AVB, n (%) 9 (35)* 13 (20) 8 (31) 5 (10)
Sustained VT/VF, n (%) 4 (15) 15 (23) 9 (35)* 5 (10)
Organ involvements, n (%)
Lung 15 (58) 31 (48) 13 (50) —
Skin 1 (4) 11 (17)† 11 (42)† —
Eye 4 (15) 22 (34)† 11 (42)† —
Laboratory data
BNP, pg/mL 253 (118–561) 128 (62–285) 99 (72–212) 131 (43–296)
ACE, IU/L 19.2 (14.2–25.5)* 13.0 (8.3–17.5)* 13.1 (10.3–17.6)* 9.1 (6.0–13.6)
Medications, n (%)
ACE-Is or ARBs 12 (46)* 38 (58) 17 (65) 38 (76)
b-Blockers 17 (65) 36 (55)* 15 (58)* 41 (82)
Diuretics 14 (54) 23 (35) 7 (27) 24 (48)
Statins 6 (27) 19 (29) 7 (27) 10 (20)
Imaging modalities
Ga scintigraphy positive, positive/n (%) 11/21 (52)* 25/45 (56)* 6/13 (46)* 0/6 (0)
FDG-PET positive, positive/n (%) 17/22 (77)* 40/50 (80)* 13/19 (68)* 0/6 (0)
Continuous variables are presented as median (interquartile range). ACE indicates angiotensin-converting enzyme; ACE-Is, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II
receptor blockers; AVB, atrioventricular block; BNP, brain natriuretic peptide; FDG-PET, 18F-ﬂuorodeoxyglucose–positron emission tomography; Ga, gallium; HRS, Heart Rhythm Society;
IVS, interventricular septum; JMHW, Japanese Ministry of Health and Welfare; LVEF, left ventricular ejection fraction; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.
*P<0.05 vs control.
†P<0.05 vs granulomas in myocardium.
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speciﬁcity with each criterion and the presence of myocardial
granulomas (Table 2). However, these variables had limited
sensitivity for CS diagnosis (Table 2). There were no statis-
tically signiﬁcant interactions between diagnostic accuracy of
myocardial DC and macrophage phenotypes, and sex (for the
JMHW 2007 criteria; CD163/68 macrophage ratio [odds ratio:
OR 0.07, 95% CI 0.005–1.01, P=0.051], CD68-positive
macrophages [OR 1.02, 95% CI 0.83–1.27, P=0.84], CD209-
positive DC [OR 0.94, 95% CI 0.81–1.10, P=0.48], for the HRS
2014 criteria; CD163/68 macrophage ratio [OR 0.02, 95% CI
0.0003–1.19, P=0.061], CD68-positive macrophages [OR
1.07, 95% CI 0.83–1.38, P=0.60], CD209-positive DC [OR
1.00, 95% CI 0.83–1.21, P=1.00], for the presence of
myocardial granulomas; CD163/68 macrophage ratio [OR
0.06, 95% CI 0.00008–42.63, P=0.40], CD68-positive macro-
phages [OR 0.99, 95% CI 0.65–1.51, P=0.97], CD209-positive
DC [OR 0.96, 95% CI 0.74–1.27, P=0.80]).
Discussion
The major ﬁndings of the present study were as follows: (1)
CD209-positive DC were found in the myocardium with sarcoid
granulomas, mainly in the lymphocyte layer of granulomas, and
were rarely found in the central core. On the other hand, the
Figure 2. Immunocompetent cells in myocardium with sarcoid granulomas. A, Hematoxylin and eosin
staining. B, Masson’s-trichrome staining. C, CD3-positive T-cells. D, CD68-positive macrophages. E, CD209-
positive dendritic cells. F, CD163-positive M2 macrophages. Scale bar indicates 100 lm (A through F).
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Figure 3. Immunocompetent cells in nongranuloma sections of myocardium. A, Immunohistochemical staining
for CD209-positive dendritic cells, CD163-positive M2 macrophages, CD68-positive macrophages, and CD3-
positive T-cells. B, Quantitative analyses for CD 209, CD163, CD68, and CD3-positive cells, and CD163/CD68
ratio. CS, cardiac sarcoidosis; GR, granuloma; JMHW, Japanese Ministry of Health and Welfare; HRS, Heart
Rhythm Society. Scale bar indicates 100 lm (A). *P<0.05, †P<0.01 vs control.
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number of CD163-positive M2 macrophages was quite low in
myocardium with sarcoid granulomas. (2) CD209-positive DC
and CD68-positive macrophages were more frequently
observed, and CD163-positive M2 macrophages were less
frequently observed in nongranuloma sections of CS patients
regardless of the presence or absence of myocardial granulo-
mas compared to those in the control group. (3) The
combination of decreased CD163/CD68 macrophage ratio
and increased number of CD209-positive DC in nongranuloma
sections using those cut-off values by ROC analyses demon-
strated the highest speciﬁcity (100%, 95% CI 92.9–100) for CS
diagnosis with the JMHW 2007 and the HRS 2014 criteria, and
the presence of myocardial granulomas. These ﬁndings
indicated that CD209-positive DC and CD68-positive macro-
phages might be associated with the development of granu-
lomas in sarcoid myocardial lesions. Furthermore, increased
number of DC and decreased M2 macrophages in nongranu-
loma sections of EMB samples also might be histopathological
surrogates for the diagnosis of CS even in patients without
myocardial granulomas detected by EMB.
Although the pathogenesis of sarcoidosis remains unclear,
several ﬁndings from previous studies in sarcoidosis patients,
including an increased number of oligoclonal T-cells in
bronchoalveolar lavage ﬂuid and skin granulomas, are
suggestive of an antigen-driven autoimmune disease.18,19
DC may play cardinal roles in both innate and adaptive
immunity, acting as representative antigen-presenting cells in
sarcoidosis. Indeed, DC contribute to granuloma formation in
experimental models of granulomatous disease in response to
Figure 4. Diagnostic accuracy of myocardial DC and macrophage
phenotypes in nongranuloma sections for CS diagnosis. A, JMHW
criteria. B, HRS 2014 criteria. C, CS with MG. AUC indicates area
under the curve; CS, cardiac sarcoidosis; DC, dendritic cells; HRS,
Heart Rhythm Society; JMHW, Japanese Ministry of Health and
Welfare; MG, myocardial granulomas.
Table 2. Diagnostic Accuracy of Immunocompetent Cells in
Nongranuloma Sections of Myocardium
Variables
Sensitivity, %
(95% CI)
Speciﬁcity, %
(95% CI)
For JMHW 2007 criteria
CS with and without MG: n=91 Control: n=50
CD163/CD68 ratio ≤0.70 81.4 (72.6–89.0) 84.0 (70.9–92.8)
CD68 ≥9/0.1 mm2 59.6 (48.6–69.8) 92.0 (80.8–97.8)
CD209 ≥13/0.1 mm2 64.8 (54.1–74.6) 86.0 (73.3–94.2)
CD163/CD68 ratio ≤0.70,
and CD209 ≥13/0.1 mm2
46.2 (35.6–56.9) 100 (92.9–100)
For HRS 2014 criteria
CS with and without MG: n=52 Control: n=50
CD163/CD68 ratio ≤0.67 78.0 (64.0–88.5) 84.0 (70.9–92.8)
CD68 ≥9/0.1 mm2 58.8 (44.2–72.4) 92.0 (80.8–97.8)
CD209 ≥13/0.1 mm2 69.2 (54.9–81.3) 86.0 (73.3–94.2)
CD163/CD68 ratio ≤0.67,
and CD209 ≥13/0.1 mm2
46.2 (32.2–60.5) 100 (92.9–100)
For CS with MG: n=26
Control: n=50
CD163/CD68 ratio ≤0.67 88.0 (68.8–97.5) 84.0 (70.9–92.8)
CD68 ≥11/0.1 mm2 76.0 (54.9–90.6) 96.0 (86.3–99.5)
CD209 ≥13/0.1 mm2 80.8 (60.6–93.4) 86.0 (73.3–94.2)
CD163/CD68 ratio ≤0.67,
and CD209 ≥13/0.1 mm2
65.4 (44.3–82.8) 100 (92.9–100)
CS indicates cardiac sarcoidosis; HRS, Heart Rhythm Society; JMHW, Japanese Ministry
of Health and Welfare; MG, myocardial granulomas.
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mycobacterium antigens, and recent clinical studies have
suggested that DC are the key antigen-presenting cells in
pulmonary and muscular sarcoidosis.12,13,20 Willart et al have
demonstrated that pulmonary granuloma formation is depen-
dent on the presence of DC and DC-induced T-cell prolifer-
ation, and DC are also observed in not only the lungs, but also
in skin and lymph nodes.21 In addition, DC recruitment and
CD40/CD40L system upregulation in muscular sarcoidosis
indicate that DC are involved in granulomatous inﬂammation
through antigen presentation in a Th1 immune system.13
Notably, several subtypes of DC have been described thus
far, with so-called myeloid DC (mDC) and plasmacytoid DC
(pDC) being predominant.22 Myeloid DC have been reported
to capture antigens in peripheral tissues, carry them to
draining lymph nodes, and stimulate naive T cells and induce
either Th1 or Th2 differentiation, depending on their matura-
tion stage and the type and duration of activation.23
Plasmacytoid DC are also important in the initiation and
regulation of immune responses, and enter lymph nodes
during inﬂammation, where they are able to secrete large
amounts of interferon-c in response to viral stimulation.24 It is
noteworthy that there are a larger number of mDC in
sarcoidosis bronchoalveolar lavage ﬂuid compared to normal,
and this ﬁnding is speciﬁc to sarcoidosis and not to other
inﬂammatory lung diseases.25 Furthermore, pDC were found
less frequently than mDC in the lymphocyte layers of
granulomas in muscle lesions of sarcoidosis.13 In sarcoidosis
bronchoalveolar lavage ﬂuid and blood,26,27 pDC also appear
with similar frequencies and absolute numbers to normal.
These results indicate that mDC rather than pDC play a crucial
role in the pathogenesis of sarcoidosis. Consistent with
previous reports, our present ﬁndings suggested that CD209-
positive mDC were frequently observed in the lymphocyte
layer of myocardial granulomas.
Interestingly, CD163-positive M2 macrophages were not
often found in both the central core and lymphocyte layer of
granulomas in the present study. Moreover, the CD163/CD68
macrophage ratio in nongranuloma sections in CS patients
was also signiﬁcantly decreased compared to that in controls.
Whereas M1 macrophages have a pro-inﬂammatory function,
M2 macrophages have a suppressive and immunoregulatory
function, namely, acting as anti-inﬂammatory macrophages
accompanied by enhanced interleukin-10 and interleukin-1
receptor antagonist production.28 Thus, the increased CD209-
positive DC and decreased CD163/CD68 macrophage ratio in
nongranuloma sections in CS patients indicate that the M1
macrophage-dominant pro-inﬂammatory process might pre-
cede the formation of myocardial granulomas in CS patients.
Ideally, CS should be diagnosed based on deﬁnite
histopathological evidence, representative of the presence
of noncaseating granulomas in the heart or other organs.7,8
However, quite a few cases fail to meet the HRS 2014 criteria
because of negative biopsy ﬁndings, albeit with many speciﬁc
clinical ﬁndings of CS in at least 2 involved organs and
meeting the JMHW 2007 criteria. Our present ﬁndings
demonstrated that increased CD209-positive DC and CD68-
positive macrophages were more frequently observed and
CD163-positive M2 macrophages were less frequently
observed in nongranuloma sections in CS patients with and
without myocardial granulomas compared to the control
group. Moreover, the combination of decreased CD163/
CD68 macrophage ratio, which may represent a pro-
inﬂammatory status, and increased number of CD209 above
the cut-off value in nongranuloma sections showed high
diagnostic accuracy. Therefore, these histopathological ﬁnd-
ings could be useful surrogates for the diagnosis of CS.
Several limitations of this study warrant mention. First, the
number of study patients was relatively small. The statistical
power thus might not be adequate for any negative results.
Second, we could not ﬁnd signiﬁcant proliferation of T-cells in
nongranuloma sections in CS patients without myocardial
granulomas in parallel with increased DC. However, a previous
study has shown that DC isolated from bronchoalveolar lavage
ﬂuid in sarcoidosis patients increase pro-inﬂammatory tumor
necrosis factor-a secretion without enhanced T-cell prolifera-
tion.12 Therefore, interactions between DC and T-cell prolifer-
ation are still under debate. Third, our study focused on the
histopathological ﬁndings derived from invasive and expensive
procedures. Noninvasive approaches with lower cost (eg,
biomarkers and diagnostic imaging) would be more useful
practically. Nevertheless, we believe that our current ﬁndings
may be useful for the diagnosis of CS in patients without
myocardial granulomas in EMB samples and could contribute to
the development of new diagnostic tools (eg, peripheral
immunocompetent cells or molecular imaging). Fourth, both
the JMHW and HRS criteria may be nonspeciﬁc reference
standards because of the insufﬁcient diagnostic accuracy of
these criteria for cardiac involvement.8,29 Althoughwe obtained
similar results in CS patients with the presence of myocardial
granulomas as a speciﬁc reference standard (Figure 4C), the
sample size was quite small. Finally, because all study patients
were Japanese, our ﬁndings may not be generalizable or
applicable to non-Japanese patients. Thus, validation studies in
another cohort outside Asians are warranted.
In conclusion, we identiﬁed that DC and macrophages were
more frequently observed, and M2 macrophages were less
frequently observed in both myocardial granulomas and
nongranuloma sections in CS patients compared to controls.
Furthermore, the combination of decreased M2 macrophage
ratio among all macrophages and increased DC number in
nongranuloma sections of the myocardium demonstrated high
speciﬁcity for the diagnosis of CS, suggesting the signiﬁcance
of DC and macrophage phenotypes as novel histopathological
surrogates for the diagnosis of CS.
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